Abstract
Globus Medical will announce its quarterly results on May 7, 2026, Post Market, with investors watching revenue trajectory, margins, and adjusted EPS against both company guidance and market forecasts.Market Forecast
Consensus points to Globus Medical delivering approximately 737.00 million US dollars in revenue this quarter, up 17.75% year over year, alongside an estimated EBIT of 163.20 million US dollars (up 23.80% YoY) and adjusted EPS of 0.92 (up 23.62% YoY). Forecasts do not provide explicit gross margin or net margin targets for the quarter. The core portfolio is expected to remain the primary growth engine, with momentum supported by continued integration execution and product mix breadth across implants and biologics. Enabling technologies remain the most promising near-term growth lever, with last quarter revenue contribution estimated at 39.65 million US dollars and company-level revenue growth of 25.73% year over year providing a supportive backdrop.Last Quarter Review
Globus Medical reported revenue of 826.42 million US dollars in the prior quarter, with a gross profit margin of 69.19%, GAAP net profit attributable to shareholders of 141.00 million US dollars (net profit margin 17.01% and quarter-on-quarter growth of 18.18%), and adjusted EPS of 1.28, up 52.38% year over year. A key financial highlight was the outperformance versus expectations on both revenue and adjusted EPS, followed by an increase to the full‑year 2026 adjusted EPS outlook to 4.40–4.50 and the reaffirmation of revenue guidance at 3.18–3.22 billion US dollars. Within the business mix, musculoskeletal products were the primary contributor, representing an estimated 786.77 million US dollars of last quarter revenue based on mix, while enabling technologies contributed about 39.65 million US dollars; company revenue grew 25.73% year over year in the quarter.Current Quarter Outlook (with major analytical insights)
Main business: musculoskeletal products
The main musculoskeletal franchise is positioned to drive the dollar contribution in the coming print, supported by breadth across core fixation systems, interbody devices, and complementary biologics. Given the prior quarter gross margin of 69.19%, the mix within implants and biologics will be an important determinant for margin resilience this quarter; historically, richer mix supports gross margin, while elevated promotional intensity or higher freight can bias margins lower. Execution around integration synergies and cross‑selling remains a central operating theme, and smoother logistics and salesforce harmonization can translate into steadier sequential volumes. On the revenue line, the company’s forecast for 737.00 million US dollars implies continued demand continuity and procedure utilization that tends to benefit the installed base and core product throughput. Even though there is no explicit margin forecast, an EBIT projection of 163.20 million US dollars (up 23.80% YoY) implies incremental operating leverage if revenue meets expectations and discretionary spend remains disciplined.The key watch items tied to this franchise are price/mix balance, contribution from new launches, and distributor execution. Price integrity alongside incremental adoption of newer platforms can preserve margin even as competition for procedural share fluctuates. If product mix skews toward higher‑value implants and biologics, gross margin can remain close to the prior quarter’s level even without an explicit target. Conversely, any transient supply or production cost pockets can set a slightly different gross margin trajectory; management’s operating cadence will be watched for signals on cost normalization through the remainder of 2026.
Most promising business: enabling technologies
Enabling technologies—capital and software platforms including robotics and navigation—continue to provide an attractive incremental growth vector. Last quarter’s revenue contribution is estimated at 39.65 million US dollars based on the segment mix, and the company’s total revenue grew 25.73% year over year in that period, creating a constructive base for capital‑adjacent consumables and service attachments. Install activity and utilization trends of the installed base are important for near‑term revenue capture: each incremental system placement can catalyze recurring revenue across disposables, service, and software, which can compound over time. Seasonality can influence capital cycles; nonetheless, this quarter’s revenue forecast growth of 17.75% year over year provides a supportive macro for recurring elements tied to enabling platforms.Margin implications here differ from implants: capital sales can be lumpy, but the recurring software and services elements tend to be margin‑accretive over time. A larger installed base also supports training and workflow standardization that reduces friction in procedure rooms and can lift throughput. On the other hand, order timing and hospital budget gating can create variability within a quarter. Thus, investors will likely focus on commentary around pipeline, order conversion, and the cadence of placements relative to plan, as these variables have outsized influence on quarterly variability and full‑year visibility for this category.
What may matter most for the stock this quarter
Guidance bridging and any update to the full‑year 2026 outlook may be the primary stock driver. The company’s previously updated adjusted EPS range of 4.40–4.50 and revenue range of 3.18–3.22 billion US dollars set the bar; any revision following the first‑quarter performance and second‑quarter setup is likely to drive multi‑session reactions. If management signals that first‑quarter demand is tracking ahead of internal plans with stable costs, investors may extrapolate leverage into the second half of 2026, supporting multiple resilience. Conversely, a cautious tone around capital orders, pricing, or costs could compress expectations even if the underlying quarter meets consensus.Margins will be scrutinized as a real‑time read on integration and mix. Last quarter’s 69.19% gross margin is a reference point; incremental changes in product mix, freight, and manufacturing absorption can swing gross margin by more than headline revenue would imply. Clear commentary on gross margin drivers can shape the narrative around sustainability of EBIT growth, particularly as forecasts imply a 23.80% year‑over‑year EBIT increase. Cash conversion and working capital will matter as well, especially if capital shipments and inventory normalization are in flight; healthy conversion can validate EBITDA quality and fund ongoing investments without balance‑sheet strain.
Finally, commercial execution across both the core implant franchise and enabling technologies will be in focus. Stable order intake and backlog conversion in capital products, combined with procedure throughput in implants and biologics, can validate the 17.75% revenue growth forecast for the quarter. Any acceleration in cross‑selling synergies and new account wins can add positive convexity to second‑half assumptions, while delays in hospital decision cycles could defer some capital revenue into later quarters without necessarily impairing full‑year targets.
Analyst Opinions
The balance of recent institutional views is bullish. Within the January 1, 2026 to April 30, 2026 window, multiple firms reiterated positive ratings with higher or sustained price targets, versus a smaller number of neutral stances. Based on the collected items, Buy‑leaning opinions outnumber Holds by roughly five to one.RBC Capital maintained its positive stance twice in the period, including a report in early January with a 100.00 US dollars target and a subsequent April reiteration at 115.00 US dollars, signaling confidence in revenue durability and improving earnings power as integration synergies and operating leverage accrue. Jefferies reaffirmed a Buy with a 115.00 US dollars target in January, highlighting continued execution and the potential for upside from mix and operating scale. Piper Sandler kept its Buy rating in early January and again in April, reinforcing the constructive setup around procedure‑driven revenue and the contribution from enabling platforms in the model. Wells Fargo reiterated a Buy with a 104.00 US dollars target in April, endorsing the company’s progress on revenue growth and profitability targets and suggesting the shares can re‑rate if first‑quarter trends land near the upper end of management’s implied trajectory.
The bullish camp’s thesis for the upcoming quarter centers on three pillars. First, revenue momentum remains healthy relative to comparables, with the quarter’s consensus estimate of 737.00 million US dollars implying 17.75% year‑over‑year growth despite lapping a strong fourth quarter. Analysts argue that the breadth of the core musculoskeletal portfolio, combined with integration‑enabled commercial coverage, can keep volumes on track through near‑term variability in hospital calendars. Second, margin structure is seen as resilient: an EBIT estimate of 163.20 million US dollars implies year‑over‑year growth of 23.80%, which analysts attribute to a combination of product mix, disciplined spending, and synergy capture that can offset cost pockets. While gross margin guidance has not been quantified for the quarter, the previous 69.19% gross margin provides a supportive baseline, and several analysts believe incremental accretion from product mix can defend margins even if capital mix is more muted intra‑quarter. Third, enabling technologies are viewed as a medium‑term compounder; even with capital seasonality, recurring revenue linked to the installed base supports steadier top‑line contributions across the year, a feature that Buy‑rated analysts think the market may be underappreciating.
This perspective also maps to how institutions are framing the risk‑reward around the print. On the upside, a clean revenue beat combined with stable or better‑than‑expected margins could unlock guidance tightening or a modest raise, which several Buy‑side frameworks suggest could drive multiple expansion given the alignment of volume and cost trends. Upside could also come from better conversion in capital orders or stronger-than-anticipated utilization trends within the installed base, which would have positive read‑throughs for repeat revenue streams. On the other hand, bulls acknowledge that order timing and hospital budgeting cycles can introduce quarter‑to‑quarter variance in enabling technologies; in such a case, analysts emphasize that the recurring software and service layers can smooth revenue intra‑year even if capital slips from one quarter to the next.
In sum, the prevailing analyst view anticipates an in‑line to better‑than‑expected quarter, with the emphasis on confirmation of revenue growth near 17.75% year over year and evidence of operating leverage consistent with a 23.80% EBIT growth framework. The majority see the balance of risks skewed positively into the event, anchored by improving earnings quality, a clear full‑year framework—revenue of 3.18–3.22 billion US dollars and adjusted EPS of 4.40–4.50—and identifiable drivers across both core implants and enabling technologies that can bridge quarterly variability while sustaining year‑over‑year expansion.